Free Trial

MEI Pharma (MEIP) Competitors

MEI Pharma logo
$4.42 +0.56 (+14.51%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MEIP vs. OTLK, VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, BMEA, and VNRX

Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Oncobiologics (OTLK), Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), Biomea Fusion (BMEA), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry.

MEI Pharma vs. Its Competitors

Oncobiologics (NASDAQ:OTLK) and MEI Pharma (NASDAQ:MEIP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 4.8% of Oncobiologics shares are held by company insiders. Comparatively, 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MEI Pharma has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncobiologicsN/AN/A-$75.37M-$0.91-2.49
MEI Pharma$65.30MN/A$17.78M-$4.75-0.93

In the previous week, Oncobiologics had 2 more articles in the media than MEI Pharma. MarketBeat recorded 3 mentions for Oncobiologics and 1 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 1.87 beat Oncobiologics' score of 1.08 indicating that MEI Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Oncobiologics Positive
MEI Pharma Very Positive

Oncobiologics' return on equity of 0.00% beat MEI Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -271.12%
MEI Pharma N/A -77.00%-64.79%

Oncobiologics currently has a consensus price target of $9.60, indicating a potential upside of 323.84%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than MEI Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
MEI Pharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Oncobiologics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Summary

Oncobiologics beats MEI Pharma on 8 of the 14 factors compared between the two stocks.

Get MEI Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MEIP vs. The Competition

MetricMEI PharmaMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.44B$5.50B$9.40B
Dividend YieldN/A1.79%4.25%4.09%
P/E Ratio-0.939.1928.1319.86
Price / SalesN/A673.20424.9198.68
Price / Cash0.51160.6835.5357.53
Price / Book0.894.728.235.71
Net Income$17.78M$30.99M$3.24B$257.80M
7 Day Performance64.31%0.96%0.66%1.12%
1 Month Performance96.01%10.05%8.07%11.30%
1 Year Performance52.94%-3.54%28.44%16.88%

MEI Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MEIP
MEI Pharma
2.2111 of 5 stars
$4.42
+14.5%
N/A+37.4%$0.00$65.30M-0.93100Positive News
Gap Down
High Trading Volume
OTLK
Oncobiologics
2.5333 of 5 stars
$2.32
+12.1%
$9.60
+313.8%
-73.9%$77.88MN/A-2.5520Positive News
VRCA
Verrica Pharmaceuticals
4.4632 of 5 stars
$0.82
+1.0%
$8.00
+881.6%
-90.5%$75.38M$7.57M-0.6840
ADAP
Adaptimmune Therapeutics
1.9626 of 5 stars
$0.28
+4.6%
$1.35
+381.0%
-78.7%$74.48M$178.03M-1.04490
MIST
Milestone Pharmaceuticals
2.7377 of 5 stars
$1.38
-11.5%
$7.00
+407.2%
+1.2%$73.78M$1M-1.7730News Coverage
Analyst Revision
High Trading Volume
SRZN
Surrozen
2.7883 of 5 stars
$8.61
-1.1%
$38.50
+347.2%
-11.6%$73.73M$11.64M-0.3480News Coverage
Positive News
PYXS
Pyxis Oncology
2.4057 of 5 stars
$1.19
+2.6%
$9.00
+656.3%
-66.6%$73.72MN/A-0.7560
ANRO
Alto Neuroscience
1.9003 of 5 stars
$2.71
+4.0%
$8.50
+214.2%
-82.7%$73.22MN/A-1.16N/A
JMAC
Maxpro Capital Acquisition
N/A$5.45
-4.4%
N/A+2,791.7%$73.18MN/A0.002,021Gap Down
BMEA
Biomea Fusion
3.4159 of 5 stars
$1.94
-3.0%
$21.40
+1,003.1%
-65.9%$72.89MN/A-0.5550Analyst Forecast
VNRX
VolitionRx
2.1095 of 5 stars
$0.68
+2.5%
$3.50
+411.2%
+8.3%$71.20M$1.31M-1.9080News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MEIP) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners